Income Taxes	9 Months Ended
Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 8. – Income Taxes Income tax expense of $0 ($0 federal and state tax expense) and income tax benefit of $226 ($189 federal tax and $37 state tax benefit) was recorded for continuing operations for the three and nine months ended March 31, 2020 and 2019, respectively. In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates. At March 31, 2020, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $8,699 against the deferred tax asset so that there is no net long-term deferred income tax asset or liability at March 31, 2020. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future. The principal negative evidence that led us to determine at March 31, 2020 that all the deferred tax assets should have full valuation allowances was the three-year cumulative pre-tax loss from continuing operations as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Services Segment businesses operate. For Federal income tax purposes, at March 31, 2020, the Company had approximately $19,831 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire primarily in fiscal 2023 through fiscal 2038; however, with the enactment of the TCJA on December 22, 2017, federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 now have no expiration date. The Company’s returns for the periods prior to the fiscal year ended June 30, 2016 are no longer subject to potential federal and state income tax examination. The CARES Act included several corporate income tax changes which the Company expects to have limited impact on our income tax expense and income taxes payable. The CARES Act (1) accelerated the refund of alternative minimum tax (“AMT”) credit carry-forwards which resulted in the acceleration of the 2020 AMT refund of $153 into its 2019 return which was filed April 15, 2020, (2) allows enhanced carry-back of NOLs to prior years income taxes, but since the Company paid no prior years, this provision is expected to result in no benefit to the Company, and (3) the IRS has determined that expenses paid with forgiven CARES Paycheck Protection Program loans may not be deducted as expenses for federal income tax purposes, accordingly, the Company expects to incur approximately $3,200 of non-deductible expenses if it spends the full amount of the PPP loans it has received.

Income Taxes

9 Months Ended

Mar. 31, 2020

Note 8. – Income Taxes

Income tax expense of $0 ($0 federal and state tax expense) and income tax benefit of $226 ($189 federal tax and $37 state tax benefit) was recorded for continuing operations for the three and nine months ended March 31, 2020 and 2019, respectively.

In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates.

At March 31, 2020, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $8,699 against the deferred tax asset so that there is no net long-term deferred income tax asset or liability at March 31, 2020. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future.

The principal negative evidence that led us to determine at March 31, 2020 that all the deferred tax assets should have full valuation allowances was the three-year cumulative pre-tax loss from continuing operations as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Services Segment businesses operate.

For Federal income tax purposes, at March 31, 2020, the Company had approximately $19,831 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire primarily in fiscal 2023 through fiscal 2038; however, with the enactment of the TCJA on December 22, 2017, federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 now have no expiration date. The Company’s returns for the periods prior to the fiscal year ended June 30, 2016 are no longer subject to potential federal and state income tax examination.

The CARES Act included several corporate income tax changes which the Company expects to have limited impact on our income tax expense and income taxes payable. The CARES Act (1) accelerated the refund of alternative minimum tax (“AMT”) credit carry-forwards which resulted in the acceleration of the 2020 AMT refund of $153 into its 2019 return which was filed April 15, 2020, (2) allows enhanced carry-back of NOLs to prior years income taxes, but since the Company paid no prior years, this provision is expected to result in no benefit to the Company, and (3) the IRS has determined that expenses paid with forgiven CARES Paycheck Protection Program loans may not be deducted as expenses for federal income tax purposes, accordingly, the Company expects to incur approximately $3,200 of non-deductible expenses if it spends the full amount of the PPP loans it has received.